Icade S.A (ICAD) | Stock Overview & Key Data

What is ICAD's 52-week high and low?

In the last 52 weeks, Icade S.A reached a high of €27.98 (on September 17, 2024) and a low of €18.30 (on April 7, 2025).

What is the market cap and P/E ratio for ICAD?

Curious about Icade S.A's size and valuation? Its market capitalization stands at 1.79B. When it comes to valuation, the P/E ratio (trailing twelve months) is 45.49, and the forward P/E (looking ahead) is 6.90.

Does ICAD pay dividends? If so, what's the yield?

Yes, Icade S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 19.37%, and the company has paid an average of €4.48 per share annually over the past 3 years.

Who are Icade S.A's main competitors or similar companies to consider before investing?

When looking at Icade S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Eurobio Scientific ALERS	253.37M	Healthcare	Medical Devices	82.97%	11.92%
Affluent Medical AFME	53.31M	Healthcare	Medical Devices	-13.38%	-60.00%
Carmat S.A ALCAR	24.77M	Healthcare	Medical Devices	-76.25%	-94.75%
Median Technologies ALMDT	25.56M	Healthcare	Medical Devices	-11.85%	-78.67%
Novacyt S.A ALNOV	34.88M	Healthcare	Medical Devices	-17.24%	-64.18%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Icade S.A.? (e.g., ROE, Debt/Equity)

To get a sense of Icade S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -6.72%, the Debt to Equity ratio from the most recent quarter is 108.60, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for ICAD?

Looking at Icade S.A's growth, its revenue over the trailing twelve months (TTM) was €1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -13.40%, and quarterly earnings saw a YoY growth of N/A.

How much of ICAD stock is held by insiders and institutions?

Wondering who owns Icade S.A stock? Company insiders (like executives and directors) hold about 0.39% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 72.53%.

For more common questions about our data, please visit our About Data page.